摘要
目的:探讨双联抗血小板治疗老年冠心病患者的疗效及安全性。方法:选取2015年2月至2018年2月间于新余市第四医院治疗的80例冠心病老年患者,随机均分为对照组和观察组,各40例,对照组给予阿司匹林治疗,观察组给予阿司匹林联合氯吡格雷治疗,分析两组间的治疗效果,分析比较其治疗前后心绞痛发作时间、次数与间隔时间,血小板计数和聚集率以及凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)和凝血酶时间(TT),记录在治疗期间两组患者的不良反应。结果:治疗后观察组治疗总有效率高于对照组(P<0.05);治疗4周后,观察组心绞痛发作时间、次数与血小板聚集率低于对照组(P<0.05),且发作间隔时间高于对照组(P<0.05);观察组治疗后PT、APTT、TT高于对照组(P<0.05);治疗期间两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:双联抗血小板治疗高龄冠心病时,可发挥抗血小板作用,缓解患者心绞痛,改善患者凝血功能,发挥良好的疗效且安全性好。
Objective:To explore curative effect and safety of dual anti-platelet therapy for elderly patients with coronary heart disease(CHD).Methods:80 elderly CHD patients who were treated in the Fourth Hospital of Xinyu City from February 2015 to February 2018 were enrolled.They were randomly divided into control group and observation group,40 cases in each group.The control group was given aspirin,and the observation group was given aspirin combined with clopidogrel.The curative effect in both groups was analyzed.The duration,frequency and interval of angina onset,platelet count and aggregation rate,prothrombin time(PT),activated partial thromboplastin time(APTT)and thrombin time(TT)before and after treatment were analyzed and compared between the two groups.The adverse reactions during treatment in both groups were recorded.Results:After treatment,total response rate of treatment in observation group was significantly higher than that in control group(P<0.05).After 4 weeks of treatment,duration and frequency of angina,platelet aggregation rate in observation group were significantly lower than those in control group(P<0.05),while onset interval time was significantly longer than that in control group(P<0.05).After treatment,PT,APTT and TT in observation group were significantly higher than those in control group(P<0.05).There was no significant difference in incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:DAPT can play anti-platelet effect in treatment of elderly CHD patients,alleviate angina,improve coagulation function,with good curative effect and safety.
作者
章丁华
ZHANG Dinghua(The Fourth Hospital of Xinyu,Xinyu Jiangxi 338000,China)
出处
《药品评价》
CAS
2021年第3期166-169,共4页
Drug Evaluation